

March 6, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

Sub: General Update – Designation of Nirma Limited as a new promoter of the Company

We refer to our letters dated September 21, 2023 and March 6, 2024 in relation to the share purchase agreement dated September 21, 2023 (“Share Purchase Agreement”) among the Company, Glenmark Pharmaceuticals Limited (“GPL”) and Nirma Limited (“Nirma”) for the sale of 91,895,379 equity shares representing 75% of the current issued and paid-up equity share capital of the Company, by GPL to Nirma Limited.

Pursuant to the Share Purchase Agreement, 6,73,89,944 equity shares representing 55% of the issued and paid-up equity share capital of the Company have been transferred by GPL to Nirma Limited. Accordingly, Nirma stands designated as a new promoter of the Company.

Nirma Limited alongwith the Company will explore other permissible methods to increase its public shareholding, to the required extent, in compliance with applicable laws by August 5, 2024.

This is for your information and records.

For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary and Compliance Officer